000141422 001__ 141422
000141422 005__ 20240229121827.0
000141422 0247_ $$2doi$$a10.1210/jc.2018-01522
000141422 0247_ $$2pmid$$apmid:30418614
000141422 0247_ $$2ISSN$$a0021-972X
000141422 0247_ $$2ISSN$$a0368-1610
000141422 0247_ $$2ISSN$$a1945-7197
000141422 0247_ $$2ISSN$$a2578-7241
000141422 0247_ $$2altmetric$$aaltmetric:51144194
000141422 037__ $$aDKFZ-2018-01928
000141422 041__ $$aeng
000141422 082__ $$a610
000141422 1001_ $$aZheng, Ju-Sheng$$b0
000141422 245__ $$aAssociation of plasma vitamin D metabolites with incident type 2 diabetes: EPIC-InterAct case-cohort study.
000141422 260__ $$aOxford$$bOxford University Press$$c2019
000141422 3367_ $$2DRIVER$$aarticle
000141422 3367_ $$2DataCite$$aOutput Types/Journal article
000141422 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1582282187_27362
000141422 3367_ $$2BibTeX$$aARTICLE
000141422 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141422 3367_ $$00$$2EndNote$$aJournal Article
000141422 520__ $$aExisting evidence for the prospective association of vitamin D status with type 2 diabetes (T2D) is focused almost exclusively on circulating total 25-hydroxyvitamin D [25(OH)D] without distinction between its subtypes: non-epimeric and epimeric 25(OH)D3 stereoisomers; and 25(OH)D2, the minor component of 25(OH)D. We aimed to investigate the prospective associations of circulating levels of the sum and each of these three metabolites with incident T2D.This analysis in the EPIC-InterAct case-cohort study for T2D included 9671 incident T2D cases and 13562 subcohort members. Plasma vitamin D metabolites were quantified by liquid-chromatography mass-spectrometry. We used multivariable Prentice-weighted Cox regression to estimate hazard ratios (HRs) of T2D for each metabolite. Analyses were performed separately within country, and estimates combined across countries using random-effects meta-analysis.The mean concentrations (standard deviation) of total 25(OH)D, non-epimeric 25(OH)D3, epimeric 25(OH)D3 and 25(OH)D2 were 41.1 (17.2), 40.7 (17.3), 2.13 (1.31), and 8.16 (6.52) nmol/L, respectively. Plasma total 25(OH)D and non-epimeric 25(OH)D3 were inversely associated with incident T2D [multivariable-adjusted HR per 1-SD=0.81 (95%CI: 0.77, 0.86) for both variables], while epimeric 25(OH)D3 was positively associated: per 1-SD HR=1.16 (1.09, 1.25). There was no statistically significant association with T2D for 25(OH)D2 [per 1-SD HR=0.94 (0.76, 1.18)].Plasma non-epimeric 25(OH)D3 was inversely associated with incident T2D, consistent with it being the major metabolite contributing to total 25(OH)D. The positive association of the epimeric form of 25(OH)D3 with incident T2D provides novel information to assess the biological relevance of vitamin D epimerization and vitamin D subtypes in diabetes etiology.
000141422 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000141422 588__ $$aDataset connected to CrossRef, PubMed,
000141422 7001_ $$aImamura, Fumiaki$$b1
000141422 7001_ $$aSharp, Stephen J$$b2
000141422 7001_ $$avan der Schouw, Yvonne T$$b3
000141422 7001_ $$aSluijs, Ivonne$$b4
000141422 7001_ $$aGundersen, Thomas E$$b5
000141422 7001_ $$aArdanaz, Eva$$b6
000141422 7001_ $$aBoeing, Heiner$$b7
000141422 7001_ $$aBonet, Catalina$$b8
000141422 7001_ $$aGómez, Jesus Humberto$$b9
000141422 7001_ $$aDow, Courtney$$b10
000141422 7001_ $$aFagherazzi, Guy$$b11
000141422 7001_ $$aFranks, Paul W$$b12
000141422 7001_ $$aJenab, Mazda$$b13
000141422 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b14$$udkfz
000141422 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b15$$udkfz
000141422 7001_ $$aKey, Timothy J$$b16
000141422 7001_ $$aKhaw, Kay-Tee$$b17
000141422 7001_ $$aLasheras, Cristina$$b18
000141422 7001_ $$aMokoroa, Olatz$$b19
000141422 7001_ $$aMancini, Francesca Romana$$b20
000141422 7001_ $$aNilsson, Peter M$$b21
000141422 7001_ $$aOvervad, Kim$$b22
000141422 7001_ $$aPanico, Salvatore$$b23
000141422 7001_ $$aPalli, Domenico$$b24
000141422 7001_ $$aRolandsson, Olov$$b25
000141422 7001_ $$aSieri, Sabina$$b26
000141422 7001_ $$aSalamanca-Fernández, Elena$$b27
000141422 7001_ $$aSacerdote, Carlotta$$b28
000141422 7001_ $$aSpijkerman, Annemieke Mw$$b29
000141422 7001_ $$aStepien, Magdalena$$b30
000141422 7001_ $$aTjonneland, Anne$$b31
000141422 7001_ $$aTumino, Rosario$$b32
000141422 7001_ $$aButterworth, Adam S$$b33
000141422 7001_ $$aRiboli, Elio$$b34
000141422 7001_ $$aDanesh, John$$b35
000141422 7001_ $$aLangenberg, Claudia$$b36
000141422 7001_ $$aForouhi, Nita G$$b37
000141422 7001_ $$aWareham, Nicholas J$$b38
000141422 773__ $$0PERI:(DE-600)2026217-6$$a10.1210/jc.2018-01522$$n4$$p1293-1303$$tThe journal of clinical endocrinology & metabolism$$v104$$x1945-7197$$y2019
000141422 909CO $$ooai:inrepo02.dkfz.de:141422$$pVDB
000141422 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000141422 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000141422 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000141422 9141_ $$y2019
000141422 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141422 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141422 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141422 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141422 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ENDOCR METAB : 2017
000141422 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141422 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141422 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141422 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141422 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141422 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141422 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141422 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141422 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CLIN ENDOCR METAB : 2017
000141422 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000141422 980__ $$ajournal
000141422 980__ $$aVDB
000141422 980__ $$aI:(DE-He78)C020-20160331
000141422 980__ $$aUNRESTRICTED